Some content on this site is not intended for people outside of the United States.
Virology & Infectious Diseases RFP Programs
and Topics of Interest
We offer both Request for Proposal (RFP) Programs and RFP Topics of Interest. An RFP Program specifically describes the research topic and may include detailed instructions on submitting a Letter of Interest (LOI) and full proposal. RFP Topics of Interest are brief descriptions of research topics that are of interest to the company. Both RFP types can be submitted through Gilead’s online proposal submission portal, Gilead OPTICS.
RFP Programs
| Program | Description | LOI Due Date |
|---|---|---|
| HBV: B-PRO |
Evaluating the patient experience for those living with chronic hepatitis B and the patient-reported outcomes associated with HBV treatment | May 19, 2025 |
| SPEARHEAD 2.0 HDV |
Addressing HDV linkage to care barriers and understanding optimal testing and diagnosis practices | June 6, 2025 |
| GATHER AND LISTEN RFP |
Long-term outcomes for women with viral hepatitis or primary biliary cholangitis (PBC), integrating HIV and hepatitis care models and addressing social and structural barriers to care. | June 20, 2025 |
.
Gilead will evaluate all Letters of Interest (LOIs) addressing one or more of the following topic areas on a rolling basis until funds are exhausted.
Safety and efficacy of liposomal amphotericin B* alone or in combination with other antifungals
- Hematologic malignancies or disease
- Nebulized liposomal amphotericin B therapy
- Cryptococcal meningitis data, building upon but not replicating the Jarvis et al. NEJM study
- Outcomes associated with early treatment Intermittent dosing in the prophylaxis setting or as maintenance therapy
- Mucormycosis
- Talaromycosis
- Liposomal amphotericin B in breakthrough invasive fungal infections Intensive Care Unit (ICU) patients
- Renally-impaired patients
- Hepatically-impaired patients
- Post-transplant patients
Antifungal resistance
- Large multi-center, country-wide or even several country studies (No single center resistance studies)
- Large studies investigating liposomal amphotericin B in the treatment of C. Auris
Epidemiology of invasive fungal disease
- Registry data
- ICU
- Hematology
Risk evaluation
- Studies that clarify safety of azoles
- Renal dysfunction – studies that clarify safety of liposomal amphotericin B, or studies that showcase the benefits of pre-emptive renal safety care in patients treated with liposomal amphotericin B
- Other special populations, such as post-transplant
*Researchers should consider the local label or indication for liposomal amphotericin B and contact their local Gilead Medical representative for any questions.